Dermal Insulin
G. Cevc
Medizinische Biophysik - Forschungslaboratorien, Technische
Universität München, Klinikum r.d.I., Ismaningerstr. 22, D-8000 München
80, BR Deutschland
In: Frontiers in Insulin Pharmacology (M. Berger, and
F. A. Gries, eds.), Georg Thieme Verlag, Stuttgart, 1993, pp 161-169.
Novel drug carriers, Transfersomes, can penetrate spontaneously
through the intact skin and, by doing so, may carry insulin non-invasively
into the body. After any dermal insulin application in the form of Transfersomes
(Transfersulin) a therapeutically significant hypoglycaemia is observed.
This probably results, in part, from the drug release from the carriers
in the liver. The blood glucose level typically starts to decrease 90-200
min after a dermal Transfersulin application, depending on the carrier
formulation. This corresponds to a delay of some 45-160 min relative to
the effect of the subcutaneously injected regular insulin. The corresponding
maximum decrease of the blood glucose level amounts to approximately 35
plus/minus 10 % of the effect that is elicited by a subcutaneous bolus
injection of the same amount of insulin; the effect of Transfersulin lasts
several times longer, however. With optimised Transfersomes, at least
70 %, and probably more than 90 % of the percutaneously applied insulin
is biologically active.
<---- |
Startseite |
Über uns |
Corporate Factsheet |
Wissenschaft |
Publikationen |
Einsatzmöglichkeiten |
Finanzierung |
Pressemitteilungen |
Letzter Newsletter |
Pressespiegel |
Konferenzen |
Karriere |
Kontakt |
Wissenschaftliche FAQ |
Glossar |
Seitenübersicht |
Suchen |